Tess O’Meara, Hematology/Oncology Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“In response to Chen et al’s elegant work profiling molecular alterations in HER2 on T-DXd, Paolo Tarantino and I consider differential drivers of resistance in HER+ vs HER-low metastatic breast cancer.
Our take:
HER2+ breast cancers are oncogenically addicted to HER2 signaling, making HER2 target down-regulation a less viable resistance mechanism to T-DXd – payload resistance or HER2 alterations dominate.
Alternatively, HER2-low cancers are generally not addicted to HER2 signaling, so loss of HER2 expression is more common following T-DXd.”
Title: Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer
Authors: Tess A. O’Meara, Paolo Tarantino
Read the Full Article.
Other articles about breast cancer.